Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer

Cancer

Volumn 83, Issue 6, 1998, Pages 1214-1223

  Mystakidou, Kyriaki ^a   Beton, Sofia ^a   Liossi, Christina ^a   Vlachos, Lambros ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Chlorpromazine; Emesis; Far advanced cancer; Metoclopramide; Nausea; Tropisetron

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CHLORPROMAZINE; CORTICOSTEROID; DEXAMETHASONE; METOCLOPRAMIDE; TROPISETRON;

ADULT; AGED; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; EPIDURAL DRUG ADMINISTRATION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INTRATHECAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIATION INJURY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VERTIGO; VOMITING;

ADULT; AGED; ANTIEMETICS; CHLORPROMAZINE; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDOLES; MALE; METOCLOPRAMIDE; MIDDLE AGED; NAUSEA; NEOPLASMS; PROSPECTIVE STUDIES; VOMITING;

EID: 0032530127     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1214::AID-CNCR22>3.0.CO;2-7     Document Type: Article

References (17)

1. Reuben DB, Mar V. Nausea and vomiting in terminal cancer patients. Arch Intern Med 1983; 146:2021-3.
2. Dunlop GM. A study of the relative frequency and importance of gastrointestinal symptoms and weakness in patients with far advanced cancer. Palliat Med 1989;4:37-43.
3. Doyle D, Hanks GWC, Macdonald N. Nausea and vomiting. In: Oxford Textbook of Palliative Medicine, 1995, pp. 282-9.
4. Fortner CL, Finley RS, Grove WR. Combination antiemetic therapy in the control of chemotherapy induced emesis. Drug Intell Clin Pharm 1985;19:21-4.
5. Bakowski MT. Advances in antiemetic therapy. Cancer Treat Rep 1984;11:237-56.
6. Kris MG, Gralla RJ, Clark RA. Consecutive dose finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone. Cancer Treat Rep 1985;69(11): 1257-62.
7. Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. BMJ 1985;291:930-2.
8. Miner WD, Sagner GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 1986;88:497-9.
9. Schmidt M, Sorbe B, Hogberg T. Efficacy and tolerability of tropisetron and dexamethasone in the control of nausea and vomiting induced by cisplatin, Ann Oncol 1993;4(3 Suppl):31.
10. Sorbe B, Beglind A-M. Tropisetron, a new 5-HT3 receptor antagonist, in the prevention of the radiation induced nausea, vomiting and diarrhoea. Drugs 1992;43(3 Suppl):33-9.
11. Zomers PJW, Langenberg CJM, de Bruijin KM. Tropisetron in the prevention of postoperative nausea and vomiting in gynaecological patients. Ann Oncol 1993;4(3 Suppl):47.
12. Mystakidou K, Befon S, Trifyllis J, Liossi C, Papadimitriou J. Tropisetron versus Metoclopramide in the control of emesis in far-advanced cancer. Oncologist 1997;2:319-23.
13. Mitchelson F. Pharmacological agents affecting emesis. A review. Drugs 1992;43:295-315.
14. Doyle D, Hanks GWC, Macdonald N. Nausea and vomiting. In: Oxford Textbook of Palliative Medicine, 1995, p. 285.
15. Lee CR, Plosker GL, McTavish D. Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential as an antiemetic. Drugs 1993;46:925-43.
16. Higgins GA, Kilpatrick GJ, Bunce KT. 5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin induced emesis in the ferret. Br J Pharmacol 1989;97:247-55.
17. Richardson BP, Engel G, Donatsh P, Stadler PA. Identification of serotonin -M receptor subtypes and their specific blockade by a new class of drugs. Nature 1985;316:126-31.